Quinupramine

Quinupramine

SCHEMBL49100

c1ccc2c(c1)CCc1ccccc1N2C1CN2CCC1CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 3/20 1.00
CHRM1 P11229 3/20 1.00
HTR1A P08908 1/20 1.00
ADRA2A P08913 1/20 1.00
DRD1 P21728 1/20 1.00
SLC6A2 P23975 1/20 1.00
SLC6A4 P31645 1/20 1.00
ADRA1A P35348 1/20 1.00
OPRM1 P35372 1/20 1.00
DRD3 P35462 1/20 1.00
SLC6A3 Q01959 1/20 1.00
KCNH2 Q12809 1/20 1.00
CHRM3 P20309 2/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRNA7 P36544 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinupramine SCHEMBL29985275 1.00 CHRM2 (1.00) CHRM2CHRM1HTR1AADRA2ADRD1
Quinupramine SCHEMBL366044 1.00 CHRM2 (1.00) CHRM2CHRM1HTR1AADRA2ADRD1
Quinupramine SCHEMBL13280380 0.82 SLC6A4 (0.67) CHRM2CHRM1HTR1AADRA2ADRD1
SCHEMBL13471233 0.80 CHRM2 (0.66) CHRM2CHRM1HTR1AADRA2ADRD1
SCHEMBL13471238 0.80 ADRA2A (0.66) CHRM2CHRM1HTR1AADRA2ADRD1
SCHEMBL20216589 0.80 CHRM2 (0.66) CHRM2CHRM1HTR1AADRA2ADRD1
Amineptine SCHEMBL28280844 0.74 SLC6A3 (0.65) CHRM2CHRM1HTR1AADRA2ADRD1
SCHEMBL7281251 0.71 CHRM2 (0.55) CHRM2CHRM1HTR1AADRA2ADRD1
SCHEMBL7290543 0.71 CHRM2 (0.55) CHRM2CHRM1HTR1AADRA2ADRD1
SCHEMBL24903369 0.68 SLC18A3 (0.53) CHRM2CHRM1HTR1AADRA2ADRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2783 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4706649-A1 USE OF ADRENALIN FOR THE TREATMENT OF SHOCKS BIOPROJET (FR) 2026-03-11 EP claimed
US-20260001942-A1 TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO H LUNDBECK AS (DK) 2026-01-01 US claimed
WO-2025262247-A1 TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO H. LUNDBECK A/S (DK) 2025-12-26 WO claimed
EP-4479032-A1 NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS Sage Therapeutics, Inc. (US) 2024-12-25 EP claimed
EP-3706762-B1 N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO UNIV EMORY (US) 2024-10-16 EP claimed
US-20240307393-A1 PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT NATIONAL CANCER CENTER (KR) 2024-09-19 US claimed
US-20240245703-A1 TOPICAL APPLICATION OF AGENTS TO REDUCE SUN SENSITIVITY AND IMPROVE TOPICAL PHOTODYNAMIC THERAPY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-07-25 US claimed
EP-4368183-A1 PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT National Cancer Center (KR) 2024-05-15 EP claimed
CN-117597126-A Pharmaceutical composition for preventing or treating cancer comprising CDK4/6 inhibitor and tricyclic antidepressant 国立癌症中心 2024-02-23 CN claimed
EP-4295864-A2 PHENYLPROPIONIC ACID DERIVATIVES FOR MODULATING PATHOGEN ACTIVITY Research Institute at Nationwide Children's Hospital (US) 2023-12-27 EP claimed
US-20020161016-A1 As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation VIVUS LLC (F/K/A VIVUS, INC.) 2002-10-31 US claimed
US-6403597-B1 PRETREATMENT SEXUAL INTERCOURSE VIVUS, INC. 2002-06-11 US claimed
WO-2002041883-A2 AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION VIVUS, INC. (US) 2002-05-30 WO claimed
US-20020037828-A1 Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation VIVUS, INC. 2002-03-28 US claimed
US-20010008896-A1 Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation SMITH WILLIAM L (US) 2001-07-19 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5922341-A Local administration of pharmacologically active agents to treat premature ejaculation VIVUS, INCORPORATED (US) 1999-07-13 US claimed
EP-0835660-A1 Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions Merckx, Gaston Edmond Filomena (BE) 1998-04-15 EP claimed